Sunitinib combined with pemetrexed and carboplatin in patients with NSCLC and other advanced solid malignancies: maximum tolerated dose and safety results

被引：0
|
作者：
Chow, Laura Q. M. [1 ]
Blais, Normand [2 ]
Jonker, Derek J. [1 ]
Soulieres, Denis [2 ]
Laurie, Scott A. [1 ]
Diab, Sami G. [3 ]
Ruiz-Garcia, Ana [4 ]
Thall, Aron [4 ]
Chao, Richard [4 ]
Eckhardt, S. Gail [5 ]
Camidge, D. Ross [5 ]
机构：
[1] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] CHUM, Hop Notre Dame de Bon Secours, Montreal, PQ, Canada
[3] Rocky Mt Canc Ctr, Aurora, CO USA
[4] Pfizer Oncol, La Jolla, CA USA
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S672 / S672
页数：1
相关论文
共 50 条
  • [31] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Quincy S. Chu
    Randeep Sangha
    Sebastien J. Hotte
    Gwen Sergenson
    David Schnell
    Vikram K. Chand
    Hal W. Hirte
    Investigational New Drugs, 2014, 32 : 1226 - 1235
  • [32] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Chu, Quincy S.
    Sangha, Randeep
    Hotte, Sebastien J.
    Sergenson, Gwen
    Schnell, David
    Chand, Vikram K.
    Hirte, Hal W.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1226 - 1235
  • [33] Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
    Zucali, P. A.
    Simonelli, M.
    De Vincenzo, F.
    Fatuzzo, G.
    Bertossi, M.
    Perrino, M.
    Miggiano, C.
    Giordano, L.
    Bonifacio, C.
    Sposta, F. Mrakic
    Santoro, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [34] BARIS: A phase I trial to evaluate the safety and tolerability of combined nintedanib and everolimus in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
    Scheffler, M.
    Gardizi, M.
    Nogova, L.
    Michels, S.
    Woempner, C.
    Persigehl, T.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 155 - 155
  • [35] Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
    Gray, Heidi J.
    Bell-McGuinn, Katherine
    Fleming, Gini F.
    Cristea, Mihaela
    Xiong, Hao
    Sullivan, Danielle
    Luo, Yan
    McKee, Mark D.
    Munasinghe, Wijith
    Martin, Lainie P.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (03) : 507 - 514
  • [36] Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies
    Harrison, M. R.
    Jeraj, R.
    Hammers, H. J.
    Stein, M. N.
    Andrei, A.
    Perlman, S.
    Kolesar, J.
    Marnocha, R. M.
    Alberti, D. B.
    Wilding, G.
    Liu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi:: Maximum tolerated dose study
    Walsh, TJ
    Goodman, JL
    Pappas, P
    Bekersky, I
    Buell, DN
    Roden, M
    Barrett, J
    Anaissie, EJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3487 - 3496
  • [38] A PHASE 1, SAFETY AND DOSE ESCALATION STUDY OF BXQ-350 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES DEMONSTRATES THAT BXQ-350 IS WELL TOLERATED AND SHOWS SIGNS OF POTENTIAL CLINICAL ACTIVITY IN EPENDYMOMA PATIENTS
    Rixe, Olivier
    Morris, John
    Wesolowski, Robert
    Yilmaz, Emrullah
    Villano, John
    Muller, Carolyn
    Wise-Draper, Trisha
    Puduvalli, Vinay
    Curry, Richard, III
    Takigiku, Ray
    Tapolsky, Gilles
    NEURO-ONCOLOGY, 2022, 24 : 41 - 41
  • [39] Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial
    Awada, Ahmad
    Gil, Thierry
    Whenham, Nicolas
    Van Hamme, Julie
    Besse-Hammer, Tatiana
    Brendel, Erich
    Delesen, Heinz
    Joosten, Miranda C.
    Lathia, Chetan D.
    Loembe, Bienvenu A.
    Piccart-Ghebart, Martine
    Hendlisz, Alain
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1674 - 1684
  • [40] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study.
    Krebs, Matthew G.
    Johnson, Melissa L.
    Cho, Byoung Chul
    Lee, Se-Hoon
    Kudgus-Lokken, Rachel
    Zemlickis, Donna
    Mitselos, Anna
    Berkay, Eileen
    Bauml, Joshua M.
    Knoblauch, Roland E.
    Hellemans, Peter
    Minchom, Anna
    CANCER RESEARCH, 2022, 82 (12)
12345